Legal Opinion
The Medicines Company v. Mylan, Inc.
Court of Appeals for the Federal Circuit
Decided April 6, 2017No. 2015-1113, 2015-1151, 2015-1181PublishedCited by 21 opinions
1Opinion of the Court
DYK, Circuit Judge.
The Medicines Company (“Medicines”) is the owner of U.S. Patent Nos. 7,582,727 (“the ’727 patent”) and 7,598,343 (“the ’343 patent”). In response to an Abbreviated New Drug Application (“ANDA”) submitted by Mylan, Inc. (“Mylan”), Medicines filed suit in the United States District Court for the Northern District of Illinois alleging that Mylan’s ANDA infringed claims 1-3, 7-10, and 17 of the ’727 patent, and claims 1-3 and 7-11 of the ’343 patent. Mylan counterclaimed seeking a declaration that the asserted claims were invalid.
The district court held on summary judgment that…
2Cases cited35 opinions
- Edward H. Phillips v. Awh Corporation, Hopeman Brothers, Inc., and Lofton Corporation, Defendants-CrossCourt of Appeals for the Federal Circuit · 2006
- Nautilus, Inc. v. Biosig Instruments, Inc.Supreme Court of the United States · 2014
- Southwall Technologies, Inc. v. Cardinal Ig CompanyCourt of Appeals for the Federal Circuit · 1995
- Cardinal Chemical Co. v. Morton International, Inc.Supreme Court of the United States · 1993
- Scimed Life Systems, Inc. v. Advanced Cardiovascular Systems, Inc.Court of Appeals for the Federal Circuit · 2001
30 more not listed; retrieve them via the Exa API.
3Cited by21 opinions
- Niazi Licensing Corporation v. St. Jude Medical S.C., Inc.Court of Appeals for the Federal Circuit · 2022
- E.I. Du Pont De Nemours & Co. v. Unifrax I LLCCourt of Appeals for the Federal Circuit · 2019
- Zimmer Surgical, Inc. v. Stryker Corp.District Court, D. Delaware · 2019
- Medicines Company v. Hospira, Inc.Court of Appeals for the Federal Circuit · 2018
- Indivior Inc. v. Mylan Techs. Inc.District Court, D. Delaware · 2018
16 more not listed; retrieve them via the Exa API.